# RX-O2 Conditions & Research

Canonical page: https://rx-o2.com/pages/hbot-research
Selected-reference check: 2026-09-10. Not an exhaustive review or physician-review attestation.

Explore HBOT conditions and published research at RX-O2 in Scottsdale and Glendale, AZ. Compare evidence, read studies, and discuss physician-led care.

RX-O2 provides physician-led hyperbaric care in Scottsdale and Glendale, Arizona, using FDA-cleared hard-shell chambers. Patients breathe 100% medical oxygen through a mask or hood inside an air-pressurized chamber. Hyperbaric technicians are certified through the NHSA. Medical evaluation and a prescription are required. Device clearance does not establish approval for every use.

Booking: https://rx-o2.janeapp.com/
Packages: https://rx-o2.com/pages/pricing-packages
Lyme page: https://rx-o2.com/pages/hyperbaric-oxygen-therapy-lyme-disease

Scottsdale: 9035 E Pima Center Parkway #11, Scottsdale, AZ 85258; 480-270-6090.
Glendale: 5626 N 51st Ave, Glendale, AZ 85301; 623-930-0887.

Research topics include conditions studied in hospitals and laboratories; inclusion is not a claim that RX-O2 treats every condition or provides emergency hospital services.

## Addiction & opioid withdrawal
Page section: https://rx-o2.com/pages/hbot-research#condition-addiction
Context: Under study
Small pilot trials have explored HBOT alongside supervised opioid treatment. Evidence is preliminary and does not establish HBOT as a treatment for addiction.
The clinical studies below concern people receiving methadone. Animal withdrawal findings cannot establish relapse prevention or replace medications and behavioral care.
- 2025: Hyperbaric oxygen treatment attenuates naloxone-precipitated opioid withdrawal behaviors and alters microglial activity in male and female mice. (Preclinical: mouse study). https://pubmed.ncbi.nlm.nih.gov/40603599/ Reduced some physical withdrawal behaviors, without changing the motivated behaviors tested. These findings are not clinical relapse-prevention evidence.
- 2022: Hyperbaric Oxygen Therapy for Pain, Opioid Withdrawal, and Related Symptoms: A Pilot Randomized Controlled Trial. (Pilot randomized controlled trial). https://pubmed.ncbi.nlm.nih.gov/35393218/ Found promising symptom trends in adults receiving methadone; designed to support a larger study, not establish efficacy.
- 2022: Hyperbaric Oxygen to Assist Adults With Opioid Use Disorder in Reducing Methadone Dose. (Small randomized feasibility study). https://pubmed.ncbi.nlm.nih.gov/35230058/ Explored supervised methadone dose reduction. Small enrollment and incomplete treatment participation limit conclusions.

## Alzheimer’s disease & memory
Page section: https://rx-o2.com/pages/hbot-research#condition-alzheimers
Context: Under study
Human studies report signals of cognitive benefit, while newer laboratory work explores possible mechanisms. Durable benefit and effects on disease progression remain uncertain.
Cognitive scores, brain imaging, and animal findings answer different questions. HBOT has not been established as a cure or a way to reverse Alzheimer’s disease.
- 2026: Hyperbaric oxygen therapy ameliorates Alzheimer's disease pathology by restoration of mitophagy and suppressing neuroinflammation in 5xFAD mice. (Preclinical: mouse study). https://pubmed.ncbi.nlm.nih.gov/41197760/ Examined amyloid, mitochondrial recycling, and inflammation in mice. These results do not demonstrate effectiveness in people.
- 2024: Clinical evidence of hyperbaric oxygen therapy for Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/38577491/ Pooled cognitive outcomes favored HBOT; the authors called for more rigorous studies to define its clinical value.
- 2020: Hyperbaric oxygen ameliorates cognitive impairment in patients with Alzheimer's disease and amnestic mild cognitive impairment. (Controlled clinical study). https://pubmed.ncbi.nlm.nih.gov/32548235/ Reported short-term cognitive changes in Alzheimer’s disease and mild cognitive impairment; does not establish altered disease progression.

## Anoxic & hypoxic brain injury
Page section: https://rx-o2.com/pages/hbot-research#condition-anoxic-injury
Context: Under study
Small clinical reports and experimental studies explore recovery after oxygen deprivation. Evidence varies substantially by the cause, timing, and age of the patient.
Adult recovery after cardiac arrest and newborn hypoxic injury are different clinical settings. These findings do not establish routine HBOT for near-drowning recovery or all forms of brain injury.
- 2024: Hyperbaric oxygen therapy for the treatment of hypoxic/ischemic injury upon perinatal asphyxia-are we there yet? (Primarily preclinical review). https://pubmed.ncbi.nlm.nih.gov/38685945/ Reviews experimental approaches to perinatal hypoxic injury; these findings cannot be generalized to routine pediatric recovery.
- 2015: Hyperbaric oxygen can induce neuroplasticity and improve cognitive functions of patients suffering from anoxic brain damage. (Retrospective case series). https://pubmed.ncbi.nlm.nih.gov/26409406/ Reported cognitive changes in 11 people after cardiac arrest. A small uncontrolled series cannot prove efficacy.

## Arthritis & inflammatory conditions
Page section: https://rx-o2.com/pages/hbot-research#condition-arthritis
Context: Under study
Research examines inflammation, cartilage, and recovery after joint surgery. Much of the arthritis-specific evidence remains preclinical.
A trial after knee replacement addresses postoperative recovery, not reversal of osteoarthritis. Mouse studies of immune signaling do not establish clinical benefit in rheumatoid arthritis.
- 2026: Hyperbaric Oxygen Therapy Improves Subchondral Perfusion and Cartilage Integrity in Established Osteoarthritis: A Pharmacokinetic DCE-MRI and T2* Quantification Study. (Preclinical: rat study). https://pubmed.ncbi.nlm.nih.gov/42233693/ Examined cartilage and circulation in experimental osteoarthritis. It does not establish cartilage repair in patients.
- 2025: Effect of hyperbaric oxygen therapy on postoperative muscle damage and inflammation following total knee arthroplasty: a randomized controlled trial. (Randomized controlled trial). https://pubmed.ncbi.nlm.nih.gov/40594255/ Studied early recovery after knee replacement, including muscle injury and inflammation. It did not test reversal of arthritis.
- 2020: Effects of Hyperbaric Oxygen on T helper 17/regulatory T Polarization in Antigen and Collagen-induced Arthritis: Hypoxia-inducible Factor-1α as a Target. (Preclinical: mouse study). https://pubmed.ncbi.nlm.nih.gov/31993228/ Examined immune-cell responses in experimental arthritis. Clinical effectiveness in rheumatoid arthritis remains unproven.

## Autism spectrum disorder
Page section: https://rx-o2.com/pages/hbot-research#condition-autism
Context: Under study
Findings are mixed. A recent meta-analysis reported improvements, but study quality was limited and controlled trials have also found no meaningful advantage.
The studies used different pressures, oxygen concentrations, and outcomes. HBOT is not an established treatment for autism; developmental and behavioral supports remain central to care.
- 2025: The effectiveness of hyperbaric oxygen therapy in children and adolescents and with autism spectrum disorders: A systematic review and meta-analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/39826608/ Reported improvements across some outcomes, but poor study quality and substantial differences between studies limit confidence.
- 2016: Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). (Cochrane systematic review). https://pubmed.ncbi.nlm.nih.gov/27737490/ Found no evidence of benefit in the eligible controlled trial and identified ear barotrauma as a possible adverse effect.
- 2012: Hyperbaric oxygen in the treatment of childhood autism: a randomised controlled trial. (Randomized, sham-controlled trial). https://pubmed.ncbi.nlm.nih.gov/22987458/ Both groups improved; HBOT did not provide an overall clinically meaningful advantage over sham exposure.
- 2009: Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. (Randomized controlled trial). https://pubmed.ncbi.nlm.nih.gov/19284641/ Reported some improvements using 1.3 ATA and 24% oxygen. This exposure differs from medical HBOT with 100% oxygen.

## Avascular necrosis
Page section: https://rx-o2.com/pages/hbot-research#condition-avascular-necrosis
Context: Specialist clinical use
HBOT is considered by specialists for selected early-stage disease. Studies report pain and imaging changes, but comparative evidence remains inconsistent.
Stage, joint collapse, and orthopedic treatment matter. A 2025 meta-analysis did not establish superiority over comparison treatments, despite improvements within some treated groups.
- 2025: The effect of hyperbaric oxygen therapy on lesion size in early-stage femoral head avascular necrosis. (Clinical imaging study). https://pubmed.ncbi.nlm.nih.gov/40986917/ Reported reduced lesion size after treatment. Imaging change alone does not establish protection from future joint collapse.
- 2025: Application of hyperbaric oxygen therapy in femoral head necrosis: a systematic review and meta-analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/40591670/ Within-group improvements did not translate into clear superiority over comparison treatments; the authors called for stronger trials.
- 2010: Hyperbaric oxygen therapy in femoral head necrosis. (Small randomized trial with follow-up). https://pubmed.ncbi.nlm.nih.gov/20637561/ Reported early pain and movement benefits. After crossover, the long-term follow-up became observational.

## Brain & intracranial abscess
Page section: https://rx-o2.com/pages/hbot-research#condition-brain-abscess
Context: Specialist clinical use
Specialists may use HBOT alongside antibiotics and surgery in selected intracranial infections. Clinical evidence is largely observational.
This is a hospital indication. HBOT must fit within urgent infection management and must not postpone drainage, antibiotics, or neurosurgical care.
- 2025: Hyperbaric oxygen therapy for brain abscesses: A useful adjuvant treatment for a faster recovery. (Comparative observational study). https://pubmed.ncbi.nlm.nih.gov/40731157/ Reported clinical and imaging outcome differences in brain abscess care. Nonrandomized comparisons leave uncertainty about causation.
- 2021: Hyperbaric oxygen for intracranial abscess. (Specialist clinical review). https://pubmed.ncbi.nlm.nih.gov/33648039/ Discusses adjunctive HBOT in selected intracranial infections alongside definitive treatment.
- 2016: Hyperbaric oxygen therapy in spontaneous brain abscess patients: a population-based comparative cohort study. (Comparative observational cohort). https://pubmed.ncbi.nlm.nih.gov/27113742/ Reported fewer treatment failures and better outcomes with adjunctive HBOT; prospective confirmation is needed.

## Burns & thermal injury
Page section: https://rx-o2.com/pages/hbot-research#condition-burns
Context: Specialist clinical use
Burn specialists may consider adjunctive HBOT for selected injuries. Research suggests possible healing benefits, with variable results across studies.
Burn severity, timing, and access to critical care affect suitability. The published evidence does not support a guaranteed reduction in operations, hospital stay, or mortality.
- 2026: Hyperbaric Oxygen Therapy in Burn Care: A Systematic Review of Current Evidence. (Systematic review). https://pubmed.ncbi.nlm.nih.gov/41700783/ Found possible healing benefits but substantial variation and inconsistent mortality findings; stronger trials are needed.
- 2026: Adjunctive Hyperbaric Oxygen in the Treatment of Thermal Burns. (Specialist clinical review). https://pubmed.ncbi.nlm.nih.gov/42365959/ Discusses adjunctive HBOT in thermal injury, with careful selection and critical-care monitoring.

## Cancer: research & treatment-related injury
Page section: https://rx-o2.com/pages/hbot-research#condition-cancer
Context: Under study
HBOT research in cancer biology is distinct from its clinical use for selected radiation injuries. Laboratory findings do not establish HBOT as a cancer treatment.
HBOT is not a substitute for oncology treatment. Care for a person with cancer requires coordination with the oncology team, including review of current medicines and the reason for HBOT.
- 2018: Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells. (Preclinical: tumor model). https://pubmed.ncbi.nlm.nih.gov/30128223/ Investigated a liposomal chemotherapy combination. This is not evidence to recommend that combination clinically.
- 2013: The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. (Preclinical: mouse study). https://pubmed.ncbi.nlm.nih.gov/23755243/ Investigated HBOT combined with a ketogenic diet in mice. HBOT alone did not change cancer progression in this model.
- 2012: Hyperbaric oxygen therapy and cancer--a review. (Research review). https://pubmed.ncbi.nlm.nih.gov/23054400/ Reviews tumor-growth and safety questions. It does not establish HBOT as a stand-alone cancer treatment.

## Carbon monoxide poisoning
Page section: https://rx-o2.com/pages/hbot-research#condition-carbon-monoxide
Context: Specialist clinical use
HBOT is a recognized specialist option for selected carbon monoxide poisoning cases, with research examining neurological outcomes and treatment timing.
Suspected poisoning requires emergency assessment and oxygen treatment. Selection for HBOT is an urgent medical decision, not an outpatient consultation booking.
- 2026: The effects of hyperbaric oxygen dosing on the delayed neuropsychiatric sequalae of carbon monoxide poisoning. (Comparative clinical study). https://pubmed.ncbi.nlm.nih.gov/42148903/ Examines treatment pressure and later neurological outcomes. This is not a protocol recommendation for unsupervised use.
- 2017: Carbon Monoxide Poisoning: Pathogenesis, Management, and Future Directions of Therapy. (Clinical and mechanistic review). https://pubmed.ncbi.nlm.nih.gov/27753502/ Explains neurological and cardiac injury, emergency care, and the role of oxygen-based treatment.
- 2002: Hyperbaric oxygen for acute carbon monoxide poisoning. (Randomized, double-blind trial). https://pubmed.ncbi.nlm.nih.gov/12362006/ Reported fewer delayed cognitive problems after acute carbon monoxide poisoning with the regimen studied.

## Cardiovascular conditions
Page section: https://rx-o2.com/pages/hbot-research#condition-cardiovascular
Context: Under study
Early studies examine cardiac function and markers of injury. Evidence does not establish routine HBOT for heart disease.
Some research combines HBOT with other interventions, making its independent contribution uncertain. Heart conditions also affect the safety assessment before treatment.
- 2026: Combined Enhanced External Counterpulsation and Hyperbaric Oxygen Therapy in Ischemic Cardiomyopathy: Interim Results of a Prospective Study. (Interim prospective combination study). https://pubmed.ncbi.nlm.nih.gov/42102952/ Examines HBOT together with counterpulsation and standard medicines, so HBOT’s independent contribution is uncertain.
- 2026: Effects of Hyperbaric Oxygen Therapy on Myocardial Injury and Inflammatory Biomarkers: A Systematic Review With Qualitative Synthesis. (Systematic review). https://pubmed.ncbi.nlm.nih.gov/42093774/ Summarizes cardiac injury and inflammatory markers; limited, heterogeneous studies do not establish routine clinical benefit.

## Cerebral palsy
Page section: https://rx-o2.com/pages/hbot-research#condition-cerebral-palsy
Context: Under study
Trials have produced conflicting results. A large multicenter study found no advantage over pressurized air; a later small study reported added rehabilitation benefits.
Different comparison treatments and study sizes limit certainty. HBOT is not established as routine cerebral palsy care and should not replace individualized rehabilitation.
- 2023: Long-Term Effect of Hyperbaric Oxygen Therapy on Gait and Functional Balance Skills in Cerebral Palsy Children-A Randomized Clinical Trial. (Small randomized rehabilitation trial). https://pubmed.ncbi.nlm.nih.gov/36832523/ Reported gait and balance improvements with HBOT plus physical therapy. The comparison group received physical therapy without sham exposure.
- 2001: Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. HBO-CP Research Group. (Randomized multicenter trial). https://pubmed.ncbi.nlm.nih.gov/11558483/ Found similar functional improvement in HBOT and pressurized-air groups; ear problems were more common with HBOT.

## Chronic pain & CRPS
Page section: https://rx-o2.com/pages/hbot-research#condition-pain
Context: Under study
CRPS studies report improvements in pain and function, including a controlled trial. The evidence is still too limited to predict an individual response.
Pain has many causes. Results in CRPS cannot be assumed to apply to all neuropathic pain, back pain, or chronic pain syndromes.
- 2025: Hyperbaric Oxygen Therapy for Management of Complex Regional Pain Syndrome. (Clinical literature review). https://pubmed.ncbi.nlm.nih.gov/39878056/ Summarizes potential CRPS benefits while identifying a need to refine patient selection and treatment protocols.
- 2024: The Effectiveness of Hyperbaric Oxygen Treatment in Patients with Complex Regional Pain Syndrome: A Retrospective Case series. (Retrospective case series). https://pubmed.ncbi.nlm.nih.gov/39239556/ Reported pain and function changes after HBOT. Without a randomized comparator, the treatment effect remains uncertain.
- 2004: Effectiveness of hyperbaric oxygen therapy in the treatment of complex regional pain syndrome. (Randomized, placebo-controlled trial). https://pubmed.ncbi.nlm.nih.gov/15174218/ Found improvements in pain, swelling, and several wrist movement measures. Wider confirmation and longer follow-up are needed.

## Compromised grafts & flaps
Page section: https://rx-o2.com/pages/hbot-research#condition-grafts-flaps
Context: Specialist clinical use
HBOT is used as an adjunct when a graft or flap has inadequate oxygen delivery. Much of the clinical evidence comes from observational studies.
Urgent surgical assessment comes first, particularly when a correctable blood-flow problem is suspected. Findings in compromised tissue do not imply a benefit for every healthy graft.
- 2026: Hyperbaric Oxygen Therapy for Ischemic Complications After Immediate Breast Reconstruction: A Systematic Review and Meta-Analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/42270974/ Suggests potential benefit after ischemic breast reconstruction complications; studies were mostly small and observational, with low certainty.
- 2025: Hyperbaric Oxygen Therapy as an Effective Adjunctive Treatment in the Reconstruction of Tissue Defects With Graft in Diabetic Foot Patients: A Retrospective Cohort Study. (Retrospective cohort study). https://pubmed.ncbi.nlm.nih.gov/40400128/ Reported improved graft outcomes in diabetic foot reconstruction. Randomized confirmation is needed.
- 2017: Hyperbaric Oxygen Therapy for the Compromised Graft or Flap. (Clinical and mechanistic review). https://pubmed.ncbi.nlm.nih.gov/28116225/ Explains salvage of compromised tissues. Human evidence was largely case reports and series.

## Crohn’s disease & perianal fistulas
Page section: https://rx-o2.com/pages/hbot-research#condition-crohns
Context: Under study
Studies in difficult-to-treat perianal fistulas show promising results in some patients, alongside reports of disease progression despite treatment.
Two HOT-TOPIC publications follow the same 20-patient cohort. A newer small Mayo Clinic series highlights the gap between symptom relief and sustained fistula healing.
- 2025: Hyperbaric Oxygen Therapy in the Management of Refractory Perianal Crohn's Disease. (Retrospective case series). https://pubmed.ncbi.nlm.nih.gov/41095923/ Some patients reported symptom relief, but objective improvement was limited and most had progression requiring further surgery.
- 2022: Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT-TOPIC trial after 1-year follow-up. (Prospective cohort follow-up). https://pubmed.ncbi.nlm.nih.gov/35146959/ Reported maintained improvements at one year in the HOT-TOPIC cohort. This follows the same patients as the 2021 publication.
- 2021: Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease. (Prospective pilot cohort). https://pubmed.ncbi.nlm.nih.gov/33326623/ Reported clinical and imaging changes in 20 patients with refractory perianal fistulas; it was not a randomized sham-controlled trial.

## Decompression illness & gas embolism
Page section: https://rx-o2.com/pages/hbot-research#condition-decompression
Context: Specialist clinical use
Recompression and hyperbaric oxygen are central specialist treatments for decompression illness and certain gas embolisms.
These are time-sensitive emergencies requiring an appropriate emergency hyperbaric service. A research listing does not imply that RX-O2 provides every emergency service described here.
- 2026: Emergency management of cerebral air gas embolism as a complication of CT-guided lung biopsy. (Single-patient case report). https://pubmed.ncbi.nlm.nih.gov/42602711/ Describes emergency HBOT after a lung-biopsy gas embolism. A case illustrates management but cannot estimate treatment success rates.
- 2026: Decompression Sickness; Not Only in Divers: Altitude as a Risk Factor. (Retrospective clinical study). https://pubmed.ncbi.nlm.nih.gov/42345225/ Examines altitude-related decompression illness and treatment experience. This is an emergency-service context.
- 2003: Gas embolism: pathophysiology and treatment. (Clinical and physiological review). https://pubmed.ncbi.nlm.nih.gov/12950319/ Explains gas embolism and the rationale for urgent hyperbaric treatment.

## Diabetic foot ulcers & selected wounds
Page section: https://rx-o2.com/pages/hbot-research#condition-diabetic-wounds
Context: Specialist clinical use
HBOT can be considered for selected difficult-to-heal diabetic foot wounds as an addition to comprehensive wound care.
Patient selection matters. Blood flow, infection control, pressure offloading, debridement, and diabetes management remain essential; HBOT is not a treatment for diabetes itself.
- 2025: The Impact of Adjunct Hyperbaric Oxygen Therapy on Healing Diabetic Foot Ulcers: A Retrospective Case-Control Study at a Tertiary Care Center. (Retrospective case-control study). https://pubmed.ncbi.nlm.nih.gov/41552219/ Reported a favorable association, but adjustment for additional confounders reduced statistical certainty.
- 2024: Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). (Clinical guideline). https://pubmed.ncbi.nlm.nih.gov/37232034/ Conditionally supports selected adjunctive wound treatments when good standard care is insufficient; certainty remains limited.
- 2010: Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. (Randomized, placebo-controlled trial). https://pubmed.ncbi.nlm.nih.gov/20427683/ HODFU found improved healing in selected chronic diabetic foot ulcers. It supports careful selection within comprehensive wound care.

## Fatigue & ME/CFS
Page section: https://rx-o2.com/pages/hbot-research#condition-fatigue
Context: Under study
A recent prospective cohort and earlier small studies report symptom improvements. Controlled evidence is still needed to establish benefit.
Uncontrolled improvements cannot isolate a treatment effect. Fatigue also warrants evaluation for other causes, and the demands of frequent clinic visits matter for people with ME/CFS.
- 2026: Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and modulates thalamic connectivity in ME/CFS: a prospective cohort study. (Prospective observational cohort). https://pubmed.ncbi.nlm.nih.gov/42249466/ Reported improvements in ME/CFS symptoms and function alongside imaging changes. A controlled trial is needed to establish causation.
- 2013: The efficacy of hyperbaric oxygen therapy in the management of chronic fatigue syndrome. (Small uncontrolled clinical study). https://pubmed.ncbi.nlm.nih.gov/23682549/ Reported improvements in fatigue scores in 16 patients. The authors called for larger studies with control groups.

## Fibromyalgia
Page section: https://rx-o2.com/pages/hbot-research#condition-fibromyalgia
Context: Under study
Randomized studies and reviews report improvements in pain and function. The durability of benefit and the best way to select patients remain under study.
The 2026 HOTFy trial adds to this literature but used a delayed-treatment comparison, not sham exposure. Some benefits diminished after treatment stopped.
- 2026: Efficacy and safety of hyperbaric oxygen therapy for women with fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/42676947/ Found pain benefits in a small body of trials in women; quality-of-life and long-term effects remained uncertain.
- 2026: HOTFy: randomised clinical trial for hyperbaric oxygen therapy in fibromyalgia. (Randomized, delayed-treatment trial). https://pubmed.ncbi.nlm.nih.gov/42225366/ HOTFy found improvements during treatment. Some outcomes moved back toward standard-care levels after HBOT stopped; there was no sham group.
- 2023: Hyperbaric oxygen therapy compared to pharmacological intervention in fibromyalgia patients following traumatic brain injury: A randomized, controlled trial. (Randomized comparative trial). https://pubmed.ncbi.nlm.nih.gov/36897850/ Compared HBOT with medication in fibromyalgia following TBI. This selected population limits generalization to all fibromyalgia.
- 2015: Hyperbaric oxygen therapy can diminish fibromyalgia syndrome--prospective clinical trial. (Randomized crossover trial). https://pubmed.ncbi.nlm.nih.gov/26010952/ Reported improvements against a no-treatment observation period. The design did not control for all effects of the chamber experience.

## How HBOT works & treatment safety
Page section: https://rx-o2.com/pages/hbot-research#condition-foundations
Context: Background science
Research describes changes in tissue oxygenation and cellular signaling. These mechanisms help explain clinical use but do not prove benefit for every condition.
The selected reviews cover mechanisms, clinical indications, and adverse effects. Safe delivery requires appropriate equipment, trained staff, patient screening, and ongoing monitoring.
- 2017: Hyperbaric Oxygen Therapy: Side Effects Defined and Quantified. (Safety review). https://pubmed.ncbi.nlm.nih.gov/28616361/ Reviews adverse effects and the importance of weighing benefit against risk for the individual patient.
- 2017: Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. (Expert consensus guideline). https://pubmed.ncbi.nlm.nih.gov/28357821/ A framework for accepted and non-accepted indications; recommendations differ in strength and certainty. Read with the published correction.
- 2011: Hyperbaric oxygen: its mechanisms and efficacy. (Mechanistic and clinical review). https://pubmed.ncbi.nlm.nih.gov/21200283/ Explains oxygen-dependent signaling and why clinical evidence must be assessed separately for each indication.

## Interstitial cystitis & bladder pain
Page section: https://rx-o2.com/pages/hbot-research#condition-urology
Context: Under study
Small studies examine bladder pain and urinary symptoms. Evidence is limited and should be distinguished from the stronger literature on radiation cystitis.
The cause of bladder symptoms matters. Findings in one form of cystitis do not establish benefit for every urinary condition.
- 2024: The potential mechanism of treating IC/BPS with hyperbaric oxygen by reducing vascular endothelial growth inhibitor and hypoxia-inducible factor-1α. (Clinical mechanistic study). https://pubmed.ncbi.nlm.nih.gov/38812622/ Links symptom changes with tissue markers after treatment; this does not prove that the proposed pathway causes clinical benefit.
- 2011: Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan. (Small clinical case series). https://pubmed.ncbi.nlm.nih.gov/21609485/ Reported sustained symptom improvement in some treatment-resistant patients. There was no randomized comparison group.
- 2006: Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. (Randomized, sham-controlled trial). https://pubmed.ncbi.nlm.nih.gov/16952654/ Reported benefit in a subset of patients with interstitial cystitis. The small study leaves substantial uncertainty.

## Long COVID
Page section: https://rx-o2.com/pages/hbot-research#condition-long-covid
Context: Under study
Evidence is mixed: a 40-session trial reported benefits, while two 2025 trials of shorter courses found no significant advantage over comparison treatments.
Different protocols and patient groups may contribute to differing results. A positive pilot study does not resolve the uncertainty shown in sham-controlled trials.
- 2026: Community-delivered hyperbaric oxygen therapy for people affected by long COVID: a pilot study. (Community pilot study). https://pubmed.ncbi.nlm.nih.gov/42301972/ Reported symptom improvements among participants completing treatment. Controlled studies are needed to separate treatment effects from other influences.
- 2025: Effect of normobaric and hyperbaric hyperoxia treatment on symptoms and cognitive capacities in Long COVID patients: a randomised placebo-controlled, prospective, double-blind trial. (Randomized, placebo-controlled trial). https://pubmed.ncbi.nlm.nih.gov/40544138/ Found no significant differences in symptoms, function, or cognition between the four oxygen and pressure regimens studied.
- 2025: Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO): a randomised, placebo-controlled, double-blind, phase II trial. (Randomized, sham-controlled trial). https://pubmed.ncbi.nlm.nih.gov/40228859/ HOT-LoCO found no significant advantage for 10 HBOT sessions on its primary physical-function outcomes at 13 weeks.
- 2022: Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. (Randomized, sham-controlled trial). https://pubmed.ncbi.nlm.nih.gov/35821512/ Reported cognitive and symptom benefits after 40 sessions. Short follow-up and a selected patient group limit broad conclusions.

## Lyme disease
Page section: https://rx-o2.com/pages/hbot-research#condition-lyme
Context: Under study
Published HBOT evidence for persistent Lyme-related symptoms is very limited. The selected clinical publication is a single-patient case report.
A case report cannot establish effectiveness, bacterial eradication, or a standard protocol. HBOT is an off-label consideration and does not replace guideline-based Lyme evaluation and treatment.
- 2014: Hyperbaric oxygen therapy as an effective adjunctive treatment for chronic Lyme disease. (Single-patient case report). https://pubmed.ncbi.nlm.nih.gov/24726678/ Reports one patient’s experience. It cannot establish effectiveness for Lyme disease or persistent post-treatment symptoms.

## Mental health & depression
Page section: https://rx-o2.com/pages/hbot-research#condition-mental-health
Context: Under study
Recent trials and reviews explore mood symptoms, including post-stroke depression. The evidence remains preliminary and varies by diagnosis.
A result in post-stroke depression cannot be generalized to every depressive disorder. HBOT should not replace established psychiatric care or prescribed medication.
- 2026: Efficacy of hyperbaric oxygen therapy for post-stroke depression: Association with inflammatory biomarker reduction in a sham-controlled randomized trial. (Randomized, sham-controlled trial). https://pubmed.ncbi.nlm.nih.gov/42336256/ Reported short-term improvements in post-stroke depression and inflammatory markers. Long-term effectiveness remains uncertain.
- 2026: Effectiveness and safety of hyperbaric oxygen therapy for psychiatric disorders: A systematic review and meta-analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/42169234/ Suggests potential symptom benefits, but studies were generally small and results varied across diagnoses and comparison treatments.

## Migraine & cluster headache
Page section: https://rx-o2.com/pages/hbot-research#condition-migraine
Context: Under study
Small studies suggest possible relief of acute migraine. Evidence for prevention and durable benefit is limited.
Oxygen at normal atmospheric pressure for cluster headache is a different treatment from HBOT. Evidence for one should not be presented as evidence for the other.
- 2015: Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache. (Cochrane systematic review). https://pubmed.ncbi.nlm.nih.gov/26709672/ Found limited evidence for acute migraine relief with HBOT. Normal-pressure oxygen evidence for cluster headache is a separate question.
- 1998: Hyperbaric oxygen in the treatment of migraine with aura. (Small controlled clinical study). https://pubmed.ncbi.nlm.nih.gov/9529766/ Reported reduced subjective migraine pain; its small scope does not establish a preventive treatment strategy.

## Multiple sclerosis
Page section: https://rx-o2.com/pages/hbot-research#condition-multiple-sclerosis
Context: Under study
Controlled clinical evidence has not shown a meaningful overall benefit for routine MS treatment. Experimental immune findings do not overturn those results.
This topic is included to make the research transparent. A biological mechanism or favorable individual experience is not sufficient evidence of improved disease course.
- 2021: Hyperbaric Oxygen Therapy Alleviates the Autoimmune Encephalomyelitis via the Reduction of IL-17a and GM-Csf Production of Autoreactive T Cells as Well as Boosting the Immunosuppressive IL-10 in the Central Nervous System Tissue Lesions. (Preclinical: mouse study). https://pubmed.ncbi.nlm.nih.gov/34440146/ Examined immune effects in experimental autoimmune encephalomyelitis. It does not establish a treatment effect in people with MS.
- 2010: Hyperbaric oxygen therapy for multiple sclerosis. (Systematic review). https://pubmed.ncbi.nlm.nih.gov/20415839/ Found no clinically meaningful overall benefit and did not recommend routine HBOT for multiple sclerosis.
- 1987: Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial. (Randomized, placebo-controlled trial). https://pubmed.ncbi.nlm.nih.gov/3320274/ Did not change overall disease progression or relapse rate; most outcomes did not differ between groups.

## Necrotizing infections & gas gangrene
Page section: https://rx-o2.com/pages/hbot-research#condition-necrotizing-infections
Context: Specialist clinical use
HBOT may be used as an adjunct in specialist management of life-threatening soft-tissue infections. Evidence includes observational studies and reviews.
Emergency surgery, source control, and antibiotics are essential. Transfer for HBOT must not delay these treatments; most outcome comparisons are not randomized.
- 2026: Hyperbaric oxygen therapy and Fournier's gangrene: a systematic review and meta-analysis. (Meta-analysis of retrospective studies). https://pubmed.ncbi.nlm.nih.gov/41575004/ Found an association with lower mortality in Fournier’s gangrene; nonrandomized studies cannot eliminate selection bias.
- 2025: The Role of Hyperbaric Oxygen Therapy in Management of Necrotizing Soft Tissue Infection. (Clinical review). https://pubmed.ncbi.nlm.nih.gov/40429506/ Discusses adjunctive HBOT within aggressive multidisciplinary infection care; urgent surgery and antibiotics remain essential.

## Plastic surgery & postoperative recovery
Page section: https://rx-o2.com/pages/hbot-research#condition-plastic-surgery
Context: Under study
Research is strongest around threatened tissue and postoperative wound problems. Evidence for routine use after uncomplicated cosmetic surgery is less certain.
The surgical team should assess unexpected pain, skin changes, or wound breakdown promptly. Published recovery and salvage rates are not guarantees for an individual procedure.
- 2026: Current Use of Hyperbaric Oxygen Therapy in Plastic Surgery: A Systematic Review. (Systematic review). https://pubmed.ncbi.nlm.nih.gov/42559634/ Reports encouraging clinical series, but the pooled complication estimate was not statistically significant and studies were highly heterogeneous.
- 2026: Hyperbaric oxygen therapy after reconstructive breast surgery: A retrospective study. (Retrospective clinical study). https://pubmed.ncbi.nlm.nih.gov/42106115/ Describes healing after breast reconstruction. The authors explicitly note that the absence of a control group prevents causal conclusions.
- 2026: The Use of Hyperbaric Oxygen Therapy in Secondary Rhinoplasty. (Clinical review). https://pubmed.ncbi.nlm.nih.gov/42091321/ Discusses HBOT in complex secondary rhinoplasty, particularly compromised tissue. It does not establish routine benefit after uncomplicated surgery.

## PTSD & veterans’ health
Page section: https://rx-o2.com/pages/hbot-research#condition-ptsd
Context: Under study
Studies in veterans and people with PTSD report symptom improvements, but study design, durability, and the best treatment approach remain unsettled.
Veteran studies often include overlapping TBI and PTSD symptoms. A small preliminary dose-comparison study cannot establish effectiveness against placebo.
- 2026: Knowledge Gaps in Our Understanding of Hyperbaric Oxygen Therapy in Post-traumatic Stress Disorder: Current Evidence, Proposed Solutions, and Preliminary Results. (Preliminary randomized dose comparison). https://pubmed.ncbi.nlm.nih.gov/42345229/ Reports the first nine completed cases. Both groups received HBOT, and the difference between doses was not statistically significant.
- 2026: A prospective, observational program evaluation of hyperbaric oxygen therapy for veterans with posttraumatic stress disorder. (Prospective observational study). https://pubmed.ncbi.nlm.nih.gov/42166296/ Reported sustained symptom improvements in veterans. The authors call for controlled trials to confirm efficacy.
- 2018: Hyperbaric oxygen for post-concussive symptoms in United States military service members: a randomized clinical trial. (Randomized, sham-controlled trial). https://pubmed.ncbi.nlm.nih.gov/29734566/ Reported improvements in postconcussion and PTSD symptoms at 13 weeks, but the changes did not persist beyond six months.

## Radiation tissue injury
Page section: https://rx-o2.com/pages/hbot-research#condition-radiation-injury
Context: Specialist clinical use
Selected late radiation injuries are an established area of HBOT care. Research includes randomized trials, systematic reviews, and long-term follow-up.
Results differ between bladder, bowel, breast, jaw, and other tissues. The reason for treatment, prior procedures, and current symptoms guide the clinical assessment.
- 2025: Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): long-term follow-up of a randomised controlled, phase 2-3 trial. (Long-term trial follow-up). https://pubmed.ncbi.nlm.nih.gov/40291346/ RICH-ART reported sustained urinary symptom improvement over five years. After crossover, the long-term analysis lacked an untreated comparison group.
- 2024: Hyperbaric Oxygen Therapy and Late Local Toxic Effects in Patients With Irradiated Breast Cancer: A Randomized Clinical Trial. (Randomized clinical trial). https://pubmed.ncbi.nlm.nih.gov/38329746/ Offering HBOT reduced fibrosis but did not significantly reduce pain in the main analysis; findings differed among treatment completers.
- 2023: Hyperbaric oxygen therapy for late radiation tissue injury. (Cochrane systematic review). https://pubmed.ncbi.nlm.nih.gov/37585677/ Supports possible benefits for selected late radiation injuries, with uncertainty by tissue and severity and recognized adverse effects.

## Refractory osteomyelitis
Page section: https://rx-o2.com/pages/hbot-research#condition-osteomyelitis
Context: Specialist clinical use
HBOT may be considered when bone infection persists despite appropriate treatment. It is used alongside surgery and targeted antimicrobial therapy.
The evidence is largely observational and differs by infection site. A recent review of sternal infections could not establish an added HBOT effect beyond the rest of the care pathway.
- 2026: Adjunctive hyperbaric oxygen therapy for poststernotomy deep sternal wound infection, mediastinitis, and sternal osteomyelitis after cardiac surgery: a scoping review. (Scoping review). https://pubmed.ncbi.nlm.nih.gov/42449409/ Found sparse, heterogeneous evidence for sternal infections and could not isolate an added HBOT effect beyond multimodal treatment.
- 2021: Hyperbaric oxygen for refractory osteomyelitis. (Specialist clinical review). https://pubmed.ncbi.nlm.nih.gov/34390634/ Discusses adjunctive use in refractory disease and the need to reassess surgery and antibiotics if infection persists.
- 2018: Effectiveness of Hyperbaric Oxygen Therapy for the Management of Chronic Osteomyelitis: A Systematic Review of the Literature. (Systematic review). https://pubmed.ncbi.nlm.nih.gov/30035798/ Summarizes mostly cohort reports and case studies of HBOT added to antibiotics and debridement for chronic osteomyelitis.

## Respiratory illness & acute COVID research
Page section: https://rx-o2.com/pages/hbot-research#condition-respiratory
Context: Under study
Exploratory hospital studies examine oxygenation, inflammation, and recovery in acute COVID-related illness. These findings do not establish routine outpatient use.
Acute respiratory illness and long COVID are different conditions. Laboratory markers alone do not demonstrate improved survival or support using HBOT instead of emergency respiratory care.
- 2026: Metabolic reprogramming of endothelial-related pathways in COVID-19 patients treated with hyperbaric oxygen therapy: a randomized clinical trial. (Randomized-trial metabolic analysis). https://pubmed.ncbi.nlm.nih.gov/41851311/ Examines blood-metabolite changes. These are exploratory biological findings rather than proof of improved survival or routine benefit.
- 2024: Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial. (Exploratory randomized-trial substudy). https://pubmed.ncbi.nlm.nih.gov/39393522/ Studies critically ill COVID patients and biological responses. Its hospital setting and small scale limit generalization.

## Retinal artery occlusion
Page section: https://rx-o2.com/pages/hbot-research#condition-retinal-occlusion
Context: Specialist clinical use
Early specialist assessment may include HBOT for selected retinal artery occlusions. Evidence is promising but limited by heterogeneous, largely nonrandomized studies.
Sudden vision loss is an emergency. An eye and stroke assessment must not be delayed while arranging HBOT; findings do not apply to all eye disorders.
- 2026: Therapeutic Efficacy of Hyperbaric Oxygen in Central Retinal Artery Occlusion: A Systematic Review and Meta-Analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/42123263/ Suggests better outcomes with early treatment; timing, study design, and baseline differences limit certainty.
- 2026: Hyperbaric Oxygen Therapy Versus Intravenous Thrombolysis in the Treatment of Central Retinal Artery Occlusion: A Systematic Review and Meta-Analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/41976928/ Summarizes HBOT and thrombolysis studies. It does not establish superiority through a definitive head-to-head trial.
- 2017: Reversibility of retinal ischemia due to central retinal artery occlusion by hyperbaric oxygen. (Retrospective clinical study). https://pubmed.ncbi.nlm.nih.gov/28096655/ Examines visual recovery and retinal findings after HBOT. The design cannot establish the benefit for every patient with CRAO.

## Severe anemia
Page section: https://rx-o2.com/pages/hbot-research#condition-anemia
Context: Specialist clinical use
HBOT may provide temporary oxygen support in exceptional cases of severe anemia when transfusion cannot be given.
This is a hospital-level indication requiring treatment of the cause of anemia and close monitoring. It is different from routine management of iron deficiency or fatigue.
- 2024: Hyperbaric oxygen therapy in the ATLS/ACLS resuscitative management of acutely ill or severely injured patients with severe anemia: a review. (Clinical review). https://pubmed.ncbi.nlm.nih.gov/39440035/ Reviews temporary oxygen support for exceptional severe anemia in acute hospital care.
- 2021: Use of hyperbaric oxygenation as an adjunctive treatment for severe pernicious anaemia in a bloodless medicine patient. (Single-patient case report). https://pubmed.ncbi.nlm.nih.gov/33846184/ Describes HBOT alongside vitamin B12 treatment when transfusion could not be used. It does not establish routine anemia treatment.

## Sports injuries & athletic recovery
Page section: https://rx-o2.com/pages/hbot-research#condition-sports
Context: Under study
Research differs across bone, muscle, tendon, and ligament conditions. Evidence for faster athletic recovery or less soreness remains inconsistent.
Human clinical results and animal healing experiments are different levels of evidence. The studies do not support a universal percentage improvement or return-to-play promise.
- 2026: Effects of hyperbaric oxygen therapy on human musculoskeletal pathologies in clinical studies: a systematic review. (Systematic review). https://pubmed.ncbi.nlm.nih.gov/42576206/ Found more consistent findings in some bone conditions; evidence for ligament, tendon, and muscle recovery remained inconclusive.
- 2026: Effects of Hyperbaric Oxygen Therapy on Exercise-Induced Muscle Injury and Soreness: A Systematic Review and Meta-analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/40784513/ Found benefits in some muscle-injury measures but not overall exercise-related soreness; outcomes and protocols varied.
- 2001: Treatment of exercise-induced muscle injury via hyperbaric oxygen therapy. (Controlled clinical trial). https://pubmed.ncbi.nlm.nih.gov/11194109/ Found no benefit for the measured markers of exercise-induced muscle injury or soreness.

## Stem cells, aging & regenerative science
Page section: https://rx-o2.com/pages/hbot-research#condition-stem-cells
Context: Background science
Studies examine circulating progenitor cells and aging-related blood markers. Changes in these markers do not demonstrate longer life or whole-body rejuvenation.
Results depend on the population and measurement. A study in irradiated patients found much smaller cell-mobilization effects, illustrating why a single percentage should not be promised to everyone.
- 2020: Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. (Prospective biomarker study). https://pubmed.ncbi.nlm.nih.gov/33206062/ Reported changes in isolated blood-cell telomeres and senescence markers. It did not demonstrate longer life or reversal of whole-body aging.
- 2019: Only minor stem cell mobilization in head and neck irradiated patients treated with hyperbaric oxygen. (Small prospective clinical study). https://pubmed.ncbi.nlm.nih.gov/31523792/ Found only minor stem-cell mobilization in irradiated patients, illustrating that effects differ by patient group and measurement.
- 2006: Stem cell mobilization by hyperbaric oxygen. (Human and animal mechanistic study). https://pubmed.ncbi.nlm.nih.gov/16299259/ Examines circulating stem/progenitor cells and nitric-oxide signaling. Cell counts are not the same as a demonstrated clinical outcome.

## Stroke recovery
Page section: https://rx-o2.com/pages/hbot-research#condition-stroke
Context: Under study
Rehabilitation studies report mixed results. Some show improved function, while a recent pilot found no statistically significant difference between treatment groups.
Research in chronic recovery is separate from acute stroke treatment. Suspected stroke requires emergency care, and HBOT must never postpone time-sensitive stroke treatment.
- 2026: Hyperbaric oxygen therapy combined with computerized cognitive training improves global cognition and functional independence post-stroke: a randomized controlled trial. (Randomized combination-treatment trial). https://pubmed.ncbi.nlm.nih.gov/42050669/ Reported benefits from HBOT plus computerized cognitive training. The findings concern a combined rehabilitation approach.
- 2026: Role of Hyperbaric Oxygen Therapy in Rehabilitation of Stroke Patients: A Randomized Controlled Pilot Study. (Randomized pilot trial). https://pubmed.ncbi.nlm.nih.gov/41992486/ Both groups improved; between-group motor and cognitive comparisons were not statistically significant.
- 2013: Hyperbaric oxygen induces late neuroplasticity in post stroke patients--randomized, prospective trial. (Randomized crossover trial). https://pubmed.ncbi.nlm.nih.gov/23335971/ Reported improvements in chronic stroke recovery compared with a no-treatment period; it did not test acute stroke care.

## Sudden sensorineural hearing loss
Page section: https://rx-o2.com/pages/hbot-research#condition-hearing-loss
Context: Specialist clinical use
Clinical guidance supports discussing HBOT with steroids for selected sudden hearing loss. Timing is important, and recent reviews report hearing benefits.
Sudden hearing loss needs urgent ENT assessment. This evidence concerns acute sensorineural loss, not routine age-related hearing loss or tinnitus alone.
- 2025: Hyperbaric oxygen therapy for acute idiopathic sudden sensorineural hearing loss; a systematic review with meta-analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/41364864/ Found moderate evidence of hearing benefit when HBOT was added to steroid treatment; optimal dose and timing need further study.
- 2022: Hyperbaric Oxygen Therapy for Patients With Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/34709348/ Pooled randomized trials favored HBOT as part of combination treatment. The available trial population was small.
- 2019: Clinical Practice Guideline: Sudden Hearing Loss (Update). (Clinical practice guideline). https://pubmed.ncbi.nlm.nih.gov/31369359/ Describes HBOT with steroids as an option for selected sudden sensorineural hearing loss, with attention to early treatment.

## Traumatic brain injury & concussion
Page section: https://rx-o2.com/pages/hbot-research#condition-tbi
Context: Under study
Studies report mixed results in persistent concussion symptoms. Recent pooled evidence suggests benefits in some domains, while sham-controlled trials have also found no added benefit.
Mild chronic symptoms and acute severe brain injury are different clinical questions. Results depend on the population, comparison treatment, and outcome being measured.
- 2026: Effectiveness of hyperbaric oxygen in traumatic brain injury patients: A systematic review and meta-analysis. (Systematic review and meta-analysis). https://pubmed.ncbi.nlm.nih.gov/42575227/ Found benefits in some cognitive and sleep outcomes, but not several other measures; applicability to more severe TBI was limited.
- 2015: Effects of hyperbaric oxygen on symptoms and quality of life among service members with persistent postconcussion symptoms: a randomized clinical trial. (Randomized, sham-controlled trial). https://pubmed.ncbi.nlm.nih.gov/25401463/ Found no advantage over sham chamber exposure for persistent postconcussion symptoms in service members.
- 2013: Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury - randomized prospective trial. (Randomized crossover trial). https://pubmed.ncbi.nlm.nih.gov/24260334/ Reported cognitive and quality-of-life gains against an observation period. No sham exposure was used.

## Traumatic ischemia & crush injury
Page section: https://rx-o2.com/pages/hbot-research#condition-crush-injury
Context: Specialist clinical use
HBOT is an adjunctive option for selected severe injuries with compromised tissue oxygenation. Clinical research examines tissue survival and complications.
Trauma surgery, restoration of blood flow, and treatment of compartment syndrome take priority. HBOT supports a coordinated trauma pathway rather than replacing urgent treatment.
- 2025: The Experience of Hyperbaric Oxygen Therapy in Earthquake-Related Crush Injuries: Could Be Beneficial Even with Delay in Initiation. (Observational clinical study). https://pubmed.ncbi.nlm.nih.gov/41223387/ Reports outcomes after earthquake-related crush injuries. Injury severity and selection limit conclusions about HBOT’s independent effect.
- 2022: Hyperbaric Oxygen for Lower Limb Trauma (HOLLT): an international multi-centre randomised clinical trial. (Randomized multicenter trial). https://pubmed.ncbi.nlm.nih.gov/36100927/ HOLLT found less tissue necrosis and fewer late complications, but its primary composite outcome was not statistically significant.

## Ulcerative colitis
Page section: https://rx-o2.com/pages/hbot-research#condition-ulcerative-colitis
Context: Under study
Pilot trials suggest potential benefit as an adjunct, with a new 2026 study in refractory disease. Other trials have found no added benefit.
A published trial protocol describes planned research, not results. Severe flares require gastroenterology-led care; current evidence does not establish HBOT as a replacement for standard treatment.
- 2026: Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trial. (Open-label phase 2a pilot). https://pubmed.ncbi.nlm.nih.gov/42136082/ PARADOX enrolled 16 people with refractory UC and reported responses in some patients. A controlled trial is needed to confirm the findings.
- 2025: Hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for moderate to severe flares (HBOT-UC): study protocol for a multi-center, randomized, double-blind, sham-controlled trial. (Trial protocol: no results). https://pubmed.ncbi.nlm.nih.gov/40545548/ Describes a planned multicenter sham-controlled study in hospitalized UC flares. Publication of the protocol is not evidence of benefit.
- 2020: A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. (Phase 2B dose-comparison trial). https://pubmed.ncbi.nlm.nih.gov/32745306/ All participants initially received HBOT plus steroids; responders were randomized to different treatment durations. It was not an HBOT-versus-sham efficacy trial.
- 2013: Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: a prospective randomized study. (Randomized open-label trial). https://pubmed.ncbi.nlm.nih.gov/23879825/ Found no significant added benefit over conventional treatment during a severe UC attack.